ウイルスおよび非ウイルス性ベクター製造の世界市場レポート 2025年

ウイルスおよび非ウイルス性ベクター製造市場規模は、今後数年間で飛躍的な成長が見込まれます。2029年にはCAGR21.0％で220億6,000万米ドルに成長します。予測期間の成長は、遺伝子治療に対する需要の高まり、希少疾患治療への応用拡大、バイオ製造インフラへの投資の増加、精密医療の採用拡大などに起因しています。予測期間の主な動向には、次世代ウイルスベクターの開発、ベクター製造におけるCRISPRまたはcas9技術の使用の増加、スケーラブルで費用対効果の高い製造プロセスへの注力、非ウイルスベクターの採用増加、細胞および遺伝子治療製造技術の進歩が含まれます。

ウイルスおよび非ウイルス性ベクター製造市場の成長は、遺伝性疾患の有病率の増加によって促進されると予想されます。遺伝子疾患は、典型的なDNA配列の逸脱から生じる。ウイルスベクターは、治療用遺伝子を標的細胞に送達し、これらの疾患の原因となる欠陥遺伝子に対処する上で重要な役割を果たしています。非ウイルス性ベクターは一般的に生体外遺伝子治療に用いられ、体外で細胞を改変してから患者に再導入します。例えば、Versus Arthritisが2023年6月に報告したように、関節リウマチ、乾癬性関節炎、変形性関節症の患者数は増加すると予想されており、遺伝子疾患の発生率が上昇していることを浮き彫りにし、ウイルスおよび非ウイルス性ベクター製造市場の成長を促進しています。

ウイルスおよび非ウイルス性ベクター製造市場の成長は、臨床試験の増加によって牽引されると予想されます。臨床試験は、医療介入の安全性と有効性を評価するために不可欠であり、治療遺伝子を送達し、試験段階を通じてベクターの品質を保証するために、ウイルスおよび非ウイルスベクターに依存しています。2023年12月のClinicalTrials.govのデータによると、登録された臨床試験の数は増加し、登録数と完了数の両方が増加しており、遺伝子治療の臨床試験をサポートする上でこれらのベクターの極めて重要な役割を明確にし、市場の成長に寄与しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界ウイルスおよび非ウイルス性ベクター製造PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のウイルスおよび非ウイルス性ベクター製造市場：成長率分析
• 世界のウイルスおよび非ウイルス性ベクター製造市場の実績：規模と成長, 2019-2024
• 世界のウイルスおよび非ウイルス性ベクター製造市場の予測：規模と成長, 2024-2029, 2034F
• 世界ウイルスおよび非ウイルス性ベクター製造総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のウイルスおよび非ウイルス性ベクター製造市場ベクトルの種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ウイルスベクター
• 非ウイルスベクター
• 世界のウイルスおよび非ウイルス性ベクター製造市場：疾患別、実績と予測, 2019-2024, 2024-2029F, 2034F
• がん
• 遺伝性疾患
• 感染症
• 心血管疾患
• その他の病気
• 世界のウイルスおよび非ウイルス性ベクター製造市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 遺伝子治療
• ワクチン学
• 細胞療法
• その他の用途
• 世界のウイルスおよび非ウイルス性ベクター製造市場、ウイルスベクターのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• アデノウイルスベクター
• レンチウイルスベクター
• AAV（アデノ随伴ウイルス）ベクター
• レトロウイルスベクター
• その他のウイルスベクター
• 世界のウイルスおよび非ウイルス性ベクター製造市場、非ウイルスベクターのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• プラスミドDNA
• 脂質ベースのベクター
• ナノ粒子
• エレクトロポレーションベースのベクター
• その他の非ウイルスベクター

第7章 地域別・国別分析

• 世界のウイルスおよび非ウイルス性ベクター製造市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のウイルスおよび非ウイルス性ベクター製造市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ウイルスおよび非ウイルス性ベクター製造市場：競合情勢
• ウイルスおよび非ウイルス性ベクター製造市場：企業プロファイル
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
  • FUJIFILM Holdings Corporation Overview, Products and Services, Strategy and Financial Analysis
  • Regeneron Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Astellas Pharma Inc.
• Lonza Group AG
• WuXi AppTec Co Ltd.
• Catalent Inc.
• Sartorius AG
• Charles River Laboratories Inc.
• Sarepta Therapeutics Inc.
• GenScript ProBio Co. Ltd.
• TAKARA BIO Inc.
• Oxford BioMedica plc
• Beam Therapeutics Inc.
• Intellia Therapeutics Inc.
• MaxCyte Inc.
• Voyager Therapeutics Inc.
• Genethon

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• ウイルスおよび非ウイルス性ベクター製造市場2029：新たな機会を提供する国
• ウイルスおよび非ウイルス性ベクター製造市場2029：新たな機会を提供するセグメント
• ウイルスおよび非ウイルス性ベクター製造市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Viral and non-viral vector manufacturing involves the production of viral and non-viral vectors, which are tools designed to deliver genetic material into cells. Viral vectors are employed in the treatment of human diseases and find applications in anticancer and gene therapies. On the other hand, non-viral vectors are utilized for various gene therapy applications, with a particular focus on vaccine development and the treatment of cancer.

The main types of viral and non-viral vectors in manufacturing are viral vectors and non-viral vectors. Viral vectors are commonly used in gene therapy and gene editing to introduce therapeutic genes or alter the expression of existing genes in living organisms. These vectors are applied in the treatment of various diseases, including cancer, genetic diseases, infectious diseases, cardiovascular diseases, and others. They play a crucial role in gene therapy, vaccinology, cell therapy, and other related fields.

The viral and non-viral vector manufacturing vectors market research report is one of a series of new reports from The Business Research Company that provides viral and non-viral vector manufacturing vectors market statistics, including viral and non-viral vector manufacturing vectors industry global market size, regional shares, competitors with a viral and non-viral vector manufacturing vectors market share, detailed viral and non-viral vector manufacturing vectors market segments, market trends and opportunities, and any further data you may need to thrive in the viral and non-viral vector manufacturing vectors industry. This viral and non-viral vector manufacturing vectors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The viral and non-viral vector manufacturing market size has grown rapidly in recent years. It will grow from $8.67 billion in 2024 to $10.3 billion in 2025 at a compound annual growth rate (CAGR) of 18.8%. The growth in the historic period can be attributed to the rising prevalence of genetic disorders, advancements in biotechnology, increasing investments in gene therapy research, growing awareness of personalized medicine, and regulatory support for gene therapy development

The viral and non-viral vector manufacturing market size is expected to see exponential growth in the next few years. It will grow to $22.06 billion in 2029 at a compound annual growth rate (CAGR) of 21.0%. The growth in the forecast period can be attributed to rising demand for gene therapies, expanding applications in rare disease treatment, increasing investments in biomanufacturing infrastructure, and growing adoption of precision medicine. Major trends in the forecast period include the development of next-generation viral vectors, increased use of CRISPR or cas9 technology in vector manufacturing, focus on scalable and cost-effective manufacturing processes, rising adoption of non-viral vectors, and advancements in cell and gene therapy manufacturing technologies.

The growth of the viral and non-viral vector manufacturing markets is anticipated to be fueled by the increasing prevalence of genetic disorders. Genetic disorders arise from deviations in the typical DNA sequence, and viral vectors play a crucial role in delivering therapeutic genes to target cells, addressing defective genes causing these disorders. Non-viral vectors are commonly employed in ex vivo gene therapy, modifying cells outside the body before reintroducing them into the patient. For example, as reported by Versus Arthritis in June 2023, the number of people with rheumatoid arthritis, psoriatic arthritis, and osteoarthritis is expected to rise, highlighting the escalating incidence of genetic disorders and thereby propelling the growth of viral and non-viral vector manufacturing markets.

The growth of the viral and non-viral vector manufacturing markets is expected to be driven by the increasing number of clinical trials. Clinical trials, essential for evaluating the safety and efficacy of medical interventions, rely on viral and non-viral vectors to deliver therapeutic genes and ensure vector quality throughout trial phases. According to data from ClinicalTrials.gov in December 2023, the number of registered clinical trials has risen, with an increase in both registration and completion figures, underlining the pivotal role of these vectors in supporting gene therapy clinical trials and contributing to market growth.

A prominent trend in the viral and non-viral vector manufacturing markets is technological advancements. Key companies are investing in advanced solutions to maintain their market position. For instance, in August 2022, Merck KGaA launched the VirusExpress 293 Adeno-Associated Virus (AAV) Production Platform, providing a comprehensive viral vector manufacturing package. This innovative platform enables biopharmaceutical companies to streamline process development, reducing time and costs associated with clinical manufacture, showcasing the significance of technological advancements in driving market growth.

Major companies in the viral and non-viral vector manufacturing market are actively pursuing partnerships to enhance profitability. Collaborative efforts involve biopharmaceutical companies, contract development and manufacturing organizations (CDMOs), research institutions, and technology providers working together to improve efficiency, safety, and scalability of non-viral vector development and production. For instance, in September 2023, NecstGen and ProteoNic BioSciences collaborated to launch ProteoNic's 2G UNic premium vector technology, contributing to improved lentiviral (LV) vector development and production efficiency, ultimately benefiting gene therapies and non-vector processes.

In March 2023, Sartorius, a Germany-based supplier of pharmaceutical and laboratory equipment, acquired Polyplus for around $2.59 billion. This acquisition is intended to enhance Sartorius's position in the gene therapy and viral vector production markets by broadening its cell and gene therapy capabilities. Polyplus is a France-based biotechnology company specializing in the production of both viral and non-viral vectors for gene therapy applications.

Major companies operating in the viral and non-viral vector manufacturing market include Novartis AG, Thermo Fisher Scientific Inc., Merck KGaA, FUJIFILM Holdings Corporation, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Lonza Group AG, WuXi AppTec Co Ltd., Catalent Inc., Sartorius AG, Charles River Laboratories Inc., Sarepta Therapeutics Inc., GenScript ProBio Co. Ltd., TAKARA BIO Inc., Oxford BioMedica plc, Beam Therapeutics Inc., Intellia Therapeutics Inc., MaxCyte Inc., Voyager Therapeutics Inc., Genethon, MeiraGTx Holdings plc, Evox Therapeutics Ltd., Entos Pharmaceuticals Inc., LogicBio Therapeutics Inc., bluebird bio Inc., 4D Molecular Therapeutics Inc., Precision NanoSystems Inc., GenSight Biologics S.A., Abeona Therapeutics Inc., Generation Bio Co.

North America was the largest region in the viral and non-viral vector manufacturing market in 2024. The regions covered in the viral and non-viral vector manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the viral and non-viral vector manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The viral and non-viral vector manufacturing market includes revenues earned by entities by providing adeno-associated viral vectors, lentiviral vectors, retroviral vectors, adenoviral vectors, particle-based vectors, and chemical-based vectors. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Viral And Non-Viral Vector Manufacturing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on viral and non-viral vector manufacturing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for viral and non-viral vector manufacturing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The viral and non-viral vector manufacturing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Vector Type: Viral Vector; Non-Viral Vector
• 2) By Disease: Cancer; Genetic Disease; Infectious Disease; Cardiovascular Disease; Other Diseases
• 3) By Application: Gene Therapy; Vaccinology; Cell Therapy; Other Applications
• Subsegments:
• 1) By Viral Vector: Adenoviral Vectors; Lentiviral Vectors; AAV (Adeno-Associated Virus) Vectors; Retroviral Vectors; Other Viral Vectors
• 2) By Non-Viral Vector: Plasmid DNA; Lipid-Based Vectors; Nanoparticles; Electroporation-Based Vectors; Other Non-Viral Vectors
• Companies Mentioned: Novartis AG; Thermo Fisher Scientific Inc.; Merck KGaA; FUJIFILM Holdings Corporation; Regeneron Pharmaceuticals Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Viral And Non-Viral Vector Manufacturing Market Characteristics

3. Viral And Non-Viral Vector Manufacturing Market Trends And Strategies

4. Viral And Non-Viral Vector Manufacturing Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Viral And Non-Viral Vector Manufacturing Growth Analysis And Strategic Analysis Framework

• 5.1. Global Viral And Non-Viral Vector Manufacturing PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Viral And Non-Viral Vector Manufacturing Market Growth Rate Analysis
• 5.4. Global Viral And Non-Viral Vector Manufacturing Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Viral And Non-Viral Vector Manufacturing Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Viral And Non-Viral Vector Manufacturing Total Addressable Market (TAM)

6. Viral And Non-Viral Vector Manufacturing Market Segmentation

• 6.1. Global Viral And Non-Viral Vector Manufacturing Market, Segmentation By Vector Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Viral Vector
• Non-Viral Vector
• 6.2. Global Viral And Non-Viral Vector Manufacturing Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cancer
• Genetic Disease
• Infectious Disease
• Cardiovascular Disease
• Other Diseases
• 6.3. Global Viral And Non-Viral Vector Manufacturing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Gene Therapy
• Vaccinology
• Cell Therapy
• Other Applications
• 6.4. Global Viral And Non-Viral Vector Manufacturing Market, Sub-Segmentation Of Viral Vector, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Adenoviral Vectors
• Lentiviral Vectors
• AAV (Adeno-Associated Virus) Vectors
• Retroviral Vectors
• Other Viral Vectors
• 6.5. Global Viral And Non-Viral Vector Manufacturing Market, Sub-Segmentation Of Non-Viral Vector, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Plasmid DNA
• Lipid-Based Vectors
• Nanoparticles
• Electroporation-Based Vectors
• Other Non-Viral Vectors

7. Viral And Non-Viral Vector Manufacturing Market Regional And Country Analysis

• 7.1. Global Viral And Non-Viral Vector Manufacturing Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Viral And Non-Viral Vector Manufacturing Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Viral And Non-Viral Vector Manufacturing Market

• 8.1. Asia-Pacific Viral And Non-Viral Vector Manufacturing Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Viral And Non-Viral Vector Manufacturing Market, Segmentation By Vector Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Viral And Non-Viral Vector Manufacturing Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Viral And Non-Viral Vector Manufacturing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Viral And Non-Viral Vector Manufacturing Market

• 9.1. China Viral And Non-Viral Vector Manufacturing Market Overview
• 9.2. China Viral And Non-Viral Vector Manufacturing Market, Segmentation By Vector Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Viral And Non-Viral Vector Manufacturing Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Viral And Non-Viral Vector Manufacturing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Viral And Non-Viral Vector Manufacturing Market

• 10.1. India Viral And Non-Viral Vector Manufacturing Market, Segmentation By Vector Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Viral And Non-Viral Vector Manufacturing Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Viral And Non-Viral Vector Manufacturing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Viral And Non-Viral Vector Manufacturing Market

• 11.1. Japan Viral And Non-Viral Vector Manufacturing Market Overview
• 11.2. Japan Viral And Non-Viral Vector Manufacturing Market, Segmentation By Vector Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Viral And Non-Viral Vector Manufacturing Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Viral And Non-Viral Vector Manufacturing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Viral And Non-Viral Vector Manufacturing Market

• 12.1. Australia Viral And Non-Viral Vector Manufacturing Market, Segmentation By Vector Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Viral And Non-Viral Vector Manufacturing Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Viral And Non-Viral Vector Manufacturing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Viral And Non-Viral Vector Manufacturing Market

• 13.1. Indonesia Viral And Non-Viral Vector Manufacturing Market, Segmentation By Vector Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Viral And Non-Viral Vector Manufacturing Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Viral And Non-Viral Vector Manufacturing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Viral And Non-Viral Vector Manufacturing Market

• 14.1. South Korea Viral And Non-Viral Vector Manufacturing Market Overview
• 14.2. South Korea Viral And Non-Viral Vector Manufacturing Market, Segmentation By Vector Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Viral And Non-Viral Vector Manufacturing Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Viral And Non-Viral Vector Manufacturing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Viral And Non-Viral Vector Manufacturing Market

• 15.1. Western Europe Viral And Non-Viral Vector Manufacturing Market Overview
• 15.2. Western Europe Viral And Non-Viral Vector Manufacturing Market, Segmentation By Vector Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Viral And Non-Viral Vector Manufacturing Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Viral And Non-Viral Vector Manufacturing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Viral And Non-Viral Vector Manufacturing Market

• 16.1. UK Viral And Non-Viral Vector Manufacturing Market, Segmentation By Vector Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Viral And Non-Viral Vector Manufacturing Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Viral And Non-Viral Vector Manufacturing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Viral And Non-Viral Vector Manufacturing Market

• 17.1. Germany Viral And Non-Viral Vector Manufacturing Market, Segmentation By Vector Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Viral And Non-Viral Vector Manufacturing Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Viral And Non-Viral Vector Manufacturing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Viral And Non-Viral Vector Manufacturing Market

• 18.1. France Viral And Non-Viral Vector Manufacturing Market, Segmentation By Vector Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Viral And Non-Viral Vector Manufacturing Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Viral And Non-Viral Vector Manufacturing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Viral And Non-Viral Vector Manufacturing Market

• 19.1. Italy Viral And Non-Viral Vector Manufacturing Market, Segmentation By Vector Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Viral And Non-Viral Vector Manufacturing Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Viral And Non-Viral Vector Manufacturing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Viral And Non-Viral Vector Manufacturing Market

• 20.1. Spain Viral And Non-Viral Vector Manufacturing Market, Segmentation By Vector Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Viral And Non-Viral Vector Manufacturing Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Viral And Non-Viral Vector Manufacturing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Viral And Non-Viral Vector Manufacturing Market

• 21.1. Eastern Europe Viral And Non-Viral Vector Manufacturing Market Overview
• 21.2. Eastern Europe Viral And Non-Viral Vector Manufacturing Market, Segmentation By Vector Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Viral And Non-Viral Vector Manufacturing Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Viral And Non-Viral Vector Manufacturing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Viral And Non-Viral Vector Manufacturing Market

• 22.1. Russia Viral And Non-Viral Vector Manufacturing Market, Segmentation By Vector Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Viral And Non-Viral Vector Manufacturing Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Viral And Non-Viral Vector Manufacturing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Viral And Non-Viral Vector Manufacturing Market

• 23.1. North America Viral And Non-Viral Vector Manufacturing Market Overview
• 23.2. North America Viral And Non-Viral Vector Manufacturing Market, Segmentation By Vector Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Viral And Non-Viral Vector Manufacturing Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Viral And Non-Viral Vector Manufacturing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Viral And Non-Viral Vector Manufacturing Market

• 24.1. USA Viral And Non-Viral Vector Manufacturing Market Overview
• 24.2. USA Viral And Non-Viral Vector Manufacturing Market, Segmentation By Vector Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Viral And Non-Viral Vector Manufacturing Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Viral And Non-Viral Vector Manufacturing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Viral And Non-Viral Vector Manufacturing Market

• 25.1. Canada Viral And Non-Viral Vector Manufacturing Market Overview
• 25.2. Canada Viral And Non-Viral Vector Manufacturing Market, Segmentation By Vector Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Viral And Non-Viral Vector Manufacturing Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Viral And Non-Viral Vector Manufacturing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Viral And Non-Viral Vector Manufacturing Market

• 26.1. South America Viral And Non-Viral Vector Manufacturing Market Overview
• 26.2. South America Viral And Non-Viral Vector Manufacturing Market, Segmentation By Vector Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Viral And Non-Viral Vector Manufacturing Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Viral And Non-Viral Vector Manufacturing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Viral And Non-Viral Vector Manufacturing Market

• 27.1. Brazil Viral And Non-Viral Vector Manufacturing Market, Segmentation By Vector Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Viral And Non-Viral Vector Manufacturing Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Viral And Non-Viral Vector Manufacturing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Viral And Non-Viral Vector Manufacturing Market

• 28.1. Middle East Viral And Non-Viral Vector Manufacturing Market Overview
• 28.2. Middle East Viral And Non-Viral Vector Manufacturing Market, Segmentation By Vector Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Viral And Non-Viral Vector Manufacturing Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Viral And Non-Viral Vector Manufacturing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Viral And Non-Viral Vector Manufacturing Market

• 29.1. Africa Viral And Non-Viral Vector Manufacturing Market Overview
• 29.2. Africa Viral And Non-Viral Vector Manufacturing Market, Segmentation By Vector Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Viral And Non-Viral Vector Manufacturing Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Viral And Non-Viral Vector Manufacturing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Viral And Non-Viral Vector Manufacturing Market Competitive Landscape And Company Profiles

• 30.1. Viral And Non-Viral Vector Manufacturing Market Competitive Landscape
• 30.2. Viral And Non-Viral Vector Manufacturing Market Company Profiles
  • 30.2.1. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. FUJIFILM Holdings Corporation Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Regeneron Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Viral And Non-Viral Vector Manufacturing Market Other Major And Innovative Companies

• 31.1. Astellas Pharma Inc.
• 31.2. Lonza Group AG
• 31.3. WuXi AppTec Co Ltd.
• 31.4. Catalent Inc.
• 31.5. Sartorius AG
• 31.6. Charles River Laboratories Inc.
• 31.7. Sarepta Therapeutics Inc.
• 31.8. GenScript ProBio Co. Ltd.
• 31.9. TAKARA BIO Inc.
• 31.10. Oxford BioMedica plc
• 31.11. Beam Therapeutics Inc.
• 31.12. Intellia Therapeutics Inc.
• 31.13. MaxCyte Inc.
• 31.14. Voyager Therapeutics Inc.
• 31.15. Genethon

32. Global Viral And Non-Viral Vector Manufacturing Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Viral And Non-Viral Vector Manufacturing Market

34. Recent Developments In The Viral And Non-Viral Vector Manufacturing Market

35. Viral And Non-Viral Vector Manufacturing Market High Potential Countries, Segments and Strategies

• 35.1 Viral And Non-Viral Vector Manufacturing Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Viral And Non-Viral Vector Manufacturing Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Viral And Non-Viral Vector Manufacturing Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer